TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07912996: A Phase 2b, Randomized, Double-Blind, Active-Control, Parallel-Group Study to Evaluate the Safety and Efficacy of GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes

Sponsor: Gilead Sciences · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07912996 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07912996 Rescue Dossier →